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CD4+Foxp3+ regulatory T (Treg) cells originate pri-
marily from thymic differentiation, but conversion of
mature T lymphocytes to Foxp3 positivity can be
elicited by several means, including in vitro activation
in thepresenceof TGF-b. Retinoic acid (RA) increases
TGF-b-induced expression of Foxp3, through un-
knownmolecularmechanisms.We showed here that,
rather than enhancing TGF-b signaling directly in na-
ive CD4+ T cells, RA negatively regulated an accom-
panying population of CD4+ T cells with a CD44hi
memory and effector phenotype. Thesememory cells
actively inhibited the TGF-b-induced conversion of
naive CD4+ T cells through the synthesis of a set of
cytokines (IL-4, IL-21, IFN-g) whose expression was
coordinately curtailed by RA. This indirect effect
was evident in vivo and required the expression of
the RA receptor alpha. Thus, cytokine-producing
CD44hi cells actively restrain TGF-b-mediated Foxp3
expression in naive T cells, and this balance can be
shifted or fine-tuned by RA.
INTRODUCTION
Foxp3+CD4+ regulatory T (Treg) cells are central to the mainte-
nance of immunological homeostasis and tolerance in the
T lymphocyte compartment (Sakaguchi et al., 2006). This role
is exemplified by the devastating lymphoproliferation and multi-
organ autoimmunity that occur in mice or humans deficient in
this population, whether through the carrying of spontaneous
mutations (scurfy mice, IPEX patients) (Ziegler, 2006) or through
experimental lineage ablation (Kim et al., 2007). A distinct gene-
expression signature characterizes Foxp3+ Treg cells (Fontenot
et al., 2005; Huehn et al., 2004; Herman et al., 2004; Hill et al.,
2007). Foxp3 plays an important role in determining this signa-
ture but is not the master regulator it was once thought to be,
because it is neither sufficient to elicit the full Treg cell genomic758 Immunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc.profile nor strictly necessary for generation of the lineage (Gavin
et al., 2007; Lin et al., 2007; Hill et al., 2007).
Most of the Treg cells present in lymphoid organs of normal
mice are generated in the thymus (Hsieh et al., 2006; Pacholczyk
et al., 2006; Wong et al., 2007a), and the specific TCR repertoire
that distinguishes them from conventional CD4+ T cells (Tconv)
can be tracked from the thymus to peripheral lymphoid organs
(Hsieh et al., 2006; Pacholczyk et al., 2006; Wong et al., 2007b).
In addition, mature CD4+ T cells from peripheral lymphoid organs
can be converted to Foxp3 positivity in a variety of conditions: in
chronic suboptimal stimulation by agonist peptide (Kretschmer
et al., 2005; Apostolou and von Boehmer, 2004), after exposure
to orally administered agonist (Mucida et al., 2005; Coombes
et al., 2007), or during lymphopenia-driven homeostatic expan-
sion (Sun et al., 2007). Finally, activation in the presence of the
cytokines IL-2 and TGF-b in vitro can induce Foxp3 expression
in naive Tconv cells, which then acquire some characteristics of
Treg cells, including suppressive properties in some contexts
(Chen et al., 2003; Fantini et al., 2004; Wan and Flavell, 2005).
In contrast, Foxp3 expression in TGF-b-induced Treg cells is
unstable (Floess et al., 2007); these cells are not suppressive in
all assays, and converted cells acquire only a partial segment
of the genomic signature typical of Treg cells (Hill et al., 2007).
Most interesting in this context were the observations that
dendritic cells (DCs) from gut origin, in particular a CD103+ pop-
ulation from the lamina propria (LP), can markedly enhance TGF-
b-induced conversion of CD4+ T cells to the Foxp3+ phenotype
in vitro and that this effect can be ascribed to all-trans retinoic
acid (RA), which also represses differentiation to an IL-17-
secreting phenotype (Mucida et al., 2007; Sun et al., 2007;
Coombes et al., 2007; Benson et al., 2007; Elias et al., 2008).
RA, the key metabolite of Vitamin A, is an important morphogen
that affects the development and maintenance of a wide variety
of tissues, as exemplified by the pleiotrophic abnormalities that
appear in Vitamin-A-deficient embryos or adults (reviewed in
Mark et al., 2006). Concerning hematopoietic cells, RA can
have general stimulatory effects on lymphocyte responses, pos-
sibly by inhibiting apoptotic pathways (Iwata et al., 2004), and
affects natural killer (NK) cell activity by modulating interferons
and NK cell ligands (Abb et al., 1982a; Abb et al., 1982b; Cerwenka
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the homeostasis and homing of lymphoid populations of the
gut-associated lymphoid tissue (GALT). It is synthesized in abun-
dance by gut DCs (Iwata et al., 2004; Coombes et al., 2007),
induces the specific gut-homing molecules CCR9 and a4b7
integrin on T cells, and also promotes GALT-related functions
in B cells (Iwata et al., 2004; Mora et al., 2006). RA’s important
role in controlling Foxp3 expression mediated by TGF-b also
suggests that the GALT has evolved a specific system to main-
tain a balanced symbiosis between the gut flora and the immune
system (Iwata et al., 2004; Mora et al., 2006; Mucida et al., 2007;
Sun et al., 2007; Coombes et al., 2007; von Boehmer, 2007).
RA receptors (RARs) belong to the family of nuclear hormone
receptors and act as ligand-dependent transcriptional regula-
tors. There are three subtypes of RARs (RARa, RARb, and
RARg) (Chambon, 1994), all of which bind all-trans RA at high
affinity, but each has distinct developmental effects and genomic
footprints. RARa and RARg are the predominant forms ex-
pressed in immunological cells (Purton et al., 2006). More re-
cently, it has been realized that RA can also serve as an activating
ligand for the PPARb and PPARd receptors, with different effects
on cell growth and apoptosis (Schug et al., 2007).
In this context, it was clearly of interest to investigate the
molecular mechanisms by which RA promotes Foxp3 expres-
sion mediated by TGF-b. Beyond their direct effects as transac-
tivators, RARs also influence transcription by transrepression of
AP-1 activity (Nicholson et al., 1990; Salbert et al., 1993; Chen
et al., 1995; Altucci and Gronemeyer, 2001). This could conceiv-
ably affect Foxp3 expression in many ways: by altering signals
induced by T cell costimulation (Wu et al., 2006) or by disturbing
the competition between AP-1 and Foxp3 for NFAT binding (von
Boehmer, 2007) and, therefore, any downstream events. Alter-
natively, liganded RARs could potentiate TGF-b signaling. The
explorations reported here started from these premises but
ended up with a rather different conclusion, unveiling a multicell
interplay underlying RA’s action.
RESULTS
Treg Cell Conversion and Homeostasis
in RAR-Deficient Mice
Three main nuclear receptors for RA have been described. Re-
cent studies, using pharmacological inhibitors, have implicated
RARa in RA-boosted Foxp3 induction (Schambach et al., 2007;
Kang et al., 2007; Elias et al., 2008), but we felt it worthwhile to
exploit genetically deficient mice to evaluate the individual con-
tributions of the three receptors, as well as to assess the impact
of the RA pathway on Treg cell populations in vivo. Thus, mice
with loss-of-function mutations in Rara, Rarb, or Rarg (Chapellier
et al., 2002c; Chapellier et al., 2002a; Chapellier et al., 2002b)
were bred and analyzed. Purified CD4+Foxp3 T cells from each
of the mutant lines (or their control littermates) were stimulated
in vitro by CD3 monoclonal antibodies together with WT splenic
DCs and TGF-b, with or without RA. As expected, the proportion
of Foxp3+ cells was boosted by RA in cultures from control litter-
mates and from Rarb-deficient and Rarg-deficient mice, but the
effect was completely abrogated by the Rara-deficient mutation
(Figures 1A and 1B). Similarly, the induction of a4b7 integrin by
RA was dependent on RARa (Figure 1C).To investigate the impact of this blockade of RA signaling on
the selection and steady-state frequency of Treg cell populations
in vivo, we analyzed CD4+ lymphocytes from the thymus, sec-
ondary lymphoid organs, and GALT for expression of Foxp3
and CD25 (Figure 1D). Positive selection of Treg cells in the thy-
mus appeared unaffected, with the usual proportion of Foxp3+
cells among CD4+CD3hi thymocytes. Steady-state frequencies
of Treg cells were not decreased in the lymphoid organs of
Rara/ mice; if anything, they showed an increase in the LP.
Thus, a deficiency in signaling through the RARadid not decrease
the overall frequency of Treg cells, whose steady-state frequency
appears to be set by other factors. Correspondingly, Rara/
mice do not present with obvious autoimmune manifestations.
Impact of RA on the Treg Cell Signature
As reported previously, Foxp3+ cells induced by TGF-b in the
presence of IL-2 and TCR activation cannot be equated to
bona fide Treg cells, because they are missing important ele-
ments of the Treg cell gene-expression signature (Hill et al.,
2007); TGF-b-induced Foxp3 expression is unstable and can
be rapidly lost upon removal of the cytokine, consistent with a
different chromatin state at the Foxp3 locus (Floess et al.,
2007). One possible explanation for the RARa-mediated effect
of RA was that it enabled converted cells to acquire the ‘‘missing
segment’’ of the Treg cell signature, thus resulting in a more
complete and stable phenotype (in preliminary experiments,
cells converted in the presence of LP DCs did appear to better
maintain their Foxp3+ phenotype upon in vivo transfer than did
those generated in the presence of spleen [Sp] DCs; see also
Benson et al., 2007). Thus, we compared the gene-expression
profiles of Foxp3+ cells, generated by 5 days of TGF-b treatment
from sorted CD4+Foxp3 cells, in the presence of LP or Sp DCs,
the latter with or without 10 nM RA. The gene-expression profiles
were obtained from purified T cell populations, with Foxp3-eGFP
reporter mice used as donors. We focused particularly on the
transcripts that constitute the robust ‘‘Treg cell signature,’’ de-
rived from multiple data sets in a previous study (Hill et al., 2007).
In the graphs of Figure 2A, the expression profiles of Foxp3+
cells generated with TGF-b and LP DCs versus RA supplemen-
tation are compared in parallel to those from Foxp3+ cells gener-
ated simply with TGF-b and splenic DCs, a condition that leads
to less conversion (Sun et al., 2007). Although there was no
general displacement, a subtle but distinct off-diagonal shift of
the Treg cell signature transcripts was observed, those normally
overrepresented in Treg cells being, as a group, slightly more ex-
pressed in samples from the LP DC cocultures (red dots, 271
overexpressed versus 136 underexpressed, c2 p = 1.5 3
1011). Accordingly, transcripts underrepresented in Treg cells
were also underexpressed in Foxp3+ cells from LP DC cocul-
tures (blue dots, 125 versus 71, c2 p = 1.23 104). These biases
were also observed with Treg cell signature transcripts in Foxp3+
cells from RA-supplemented cultures (219 versus 188, 52 versus
144, c2 p = 4.9 3 1011). A direct comparison of transcripts af-
fected by RA or LP DCs showed a clear parallel, supporting
the notion that the ability of LP DCs to enhance Foxp3 expres-
sion is due to the production of RA (Figure S1, available online).
Thus, the presence of RA did appear to slightly reinforce the Treg
cell gene-expression signature. But did it promote complemen-
tation of the ‘‘holes,’’ i.e., those transcripts normallyImmunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc. 759
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Mediated by Retinoic Acid
(A) CD4+CD25 T cells were sorted and cultured in vitro with WT CD11c+
DCs (ratio 10:1, T cell to DC) in the presence of anti-CD3 (1 mg/ml) and
TGF-b (10 ng/ml), with or without 10 nM RA, for 5 days. Foxp3 and a4b7
expression was determined in CD4+ T cells from Rara/ mice and com-
pared to WT littermate controls (representative FACS plot from two or
more independent experiments).
(B) Summary of TGF-b-mediated conversion in cultures from WT or
Rara/, Rarb/, or Rarg/ mice treated with or without RA, as
described in (A).
(C) The effects of RARa on a4b7 expression in CD4+ T cells after treatment
with TGF-b in the presence (open histogram) or absence (filled histogram)
of RA, as described in (A). Representative FACS plot from two or more
independent experiments is shown.
(D) The proportion of CD4+Foxp3+ T cells in the lamina propria, thymus, or
spleen from WT and Rara/ mice was compared. Organs were pro-
cessed from WT or Rara/ mice, and Foxp3 and CD25 expression on
CD4+ T cells was determined by FACS. Numbers in the gates represent
the mean (± SD where applicable) for Foxp3 expression (thymus, n = 2;
spleen, n = 5; lamina propria, n = 8), and the p value was determined by
Student’s t test.
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cited Foxp3+ cells (Hill et al., 2007)? This question was ad-
dressed by the signatureMatch analysis of Figure 2B. This algo-
rithm is designed to test how well a signature is achieved in test
populations. It uses normalized expression values that are then
standardized relative to two reference populations that define
the expression minima and maxima for each transcript of the sig-
nature (here ex vivo Treg and Foxp3 Tconv cells, pops. 1 and 2).
In agreement with our previous report, in vitro activation in the
presence of IL-2 (pop. 3) induced a substantial fraction of the
Treg cell signature, and the addition of TGF-b (pop. 4) brought
forth only a minor subset of Treg cell signature transcripts (mainly
in the TGF bracket). Although there was an additional impact of
LP DCs in the cultures (pop. 5), partially mimicked by Sp DCs +
RA (pop. 7), much of the Treg cell signature transcripts remained
at the basal level of Tconv cells. Thus, the ‘‘holes’’ in the signa-
ture elicited by activation in the presence of TGF-b largely persist
in spite of RA. The FoldChange plots of Figure S2 confirmed this
impression, and there were substantial changes in only a small
number of Treg cell signature genes. This inability of RA to com-
plement the partial effect of TGF-b on the Treg cell signature is
also evident from the representation of Figure 2C, which com-
pares the effect of RA (in the presence of TGF-b) to the Treg cell
profile: only a few genes of the Treg cell signature were directly
affected in any appreciable manner by RA (e.g., Nrp1, P2rx7).
Most of the changes elicited by RA were independent of
the Treg cell signature, a conclusion bolstered by the plot of
Figure 2D, which compares the effects of RA in Foxp3+ cells ver-
sus in cells remaining Foxp3 in those cultures: RA-responsive
transcripts were very similar in both cell types. The RA signature
(listed in Tables S1 and S2) included some of the transcripts one
expects to be induced, such as Ccr9 and Itga4 (a4 integrin), but
also some repressed transcripts. It did not show any substantial
overlap with the ‘‘TGF-b signature,’’ i.e., the transcripts affected
by TGF-b treatment independently of Treg cell conversion (Hill
et al., 2007), indicating that RA does not enhance conversion
by increasing the intensity of TGF-b signaling. In contrast, the ob-
servation that the IL-6 receptor was downregulated by 75 percent
was quite suggestive because IL-6, in the presence of TGF-b,
promotes the expression of IL-17, while inhibiting that of Foxp3
(Veldhoen et al., 2006; Bettelli et al., 2006; Mangan et al., 2006;
Stockinger and Veldhoen, 2007).
IL-6 Is Only a Minor Player in RA’s Action
The repression of IL-6Ra by RA observed in the gene-expression
profiles suggested a mechanism for RA’s action: because IL-6
inhibits the induction of Foxp3, RA might simply be reducing
the sensitivity of naive T cells to inhibition by IL-6. We first con-
firmed by flow cytometry that the alpha chain of IL-6R was
indeed repressed by RA (Figure 3A; over six experiments, the
mean fluorescence intensity dropped from 526 ± 116 to 255 ±
81, p < 0.001). This regulation of IL-6Ra expression was also
lost when cells fromRara/mice were tested (Figure 3B). Under
our culture conditions, addition of recombinant IL-6 did have the
expected inhibitory effect on Foxp3 expression, and this influ-
ence was partially reversed by RA, consistent with the notion
that RA might help to relieve the inhibition by IL-6 (Figure 3C).
In contrast, RA was still very effective in cultures of cells from
IL-6-deficient mice; if anything, its influence was even strongerIthan that in cultures from WT mice (Figure 3D). Thus, an inhibition
of IL-6 action, although it may partially contribute to RA’s impact
on Foxp3 expression, particularly in IL-6-rich environments,
cannot be the main mechanism through which RA promotes
TGF-b-mediated Foxp3 expression.
RA Acts Indirectly on Treg Cell Conversion
The rather limited impact of RA on transcriptional profiles of
converted Treg cells raised the possibility of an indirect effect;
of RA acting on something other than the responding cells.
This hypothesis emerged to the forefront by a serendipitous
observation. In experiments designed to test the effect of RA
on isolated CD4+ T cell subsets, we observed that the enhancing
effect of RA was lost when the fully naive fraction of CD4+ cells
(purified as CD44loCD62Lhi) were used as responders (Figure 4A),
rather than CD4+ T cells from unfractionated splenocytes (Fig-
ure 4B). Also apparent in these experiments was that purified
naive CD4+ cells gave rise to a higher proportion of Foxp3+
convertants when cultured alone than when cultured as part of
unfractionated splenocytes (compare the left panels of Fig-
ures 4A and 4B). The insensitivity of naive CD4+ cells to RA
was not due to a saturating response to TGF-b, given that it
was also observed through suboptimal doses of TGF-b (Fig-
ure 4C). Similarly, the conversion of purified naive cells could
not be boosted through a range of RA doses (Figure 4D). This
lack of response did not mean that purified naive CD4+ T cells
were refractory to RA, given that CCR9 and the a4b7 integrin
were induced effectively in these cells by RA exposure (not
shown).
These data suggested that the increased generation of Foxp3+
cells in response to RA in these cultures of unseparated spleno-
cytes might represent the lifting of an inhibition imparted by other
cells, a dampening lifted equally by RA or by purification of the
naive responder cells. It seemed likely that the inhibitory cell
might also be a CD4+ T cell, given that it was clearly possible
to obtain strong responses to RA when whole CD4+ populations
were used as responders to TGF-b (as in the experiments of
Figures 1 and 2, and as in all of the initial descriptions of RA’s
effect [Mucida et al., 2007; Lufkin et al., 1993; Coombes et al.,
2007; Benson et al., 2007; Elias et al., 2008]). This inhibitory
population would then be predicted to have a CD44hi memory
phenotype and would thus be lost during the purification of naive
responder cells. We directly tested this hypothesis by the recon-
stitution experiments depicted in Figure 5, in which CD4+ cells
were purified as CD44-negative or CD44-positive (each identifi-
able through CD45 allotypes so as to track their fate after culture)
and admixed in stimulation cultures supplemented or not with
RA. The induction of Foxp3 in naive cells was clearly inhibited
by coculture with an equal number of CD44hi cells, an inhibition
reversed by the addition of RA (Figure 5A; several experiments
tabulated in Figure 5B). This inhibitory effect of CD44hi cells
(hereafter referred to as ‘‘counterconversion’’ for brevity), as
well as its reversal by RA, could be titrated through a range of
cell ratios (Figure 5C). This dose-response range was compatible
with the results obtained with whole CD4+ cells (e.g., Figure 4), in
which the CD44/CD44+ ratio was approximately 4.
We then asked how CD44hi memory T cells influence the TGF-
b-induced conversion of naive T cells, the production of a soluble
factor being the most likely candidate. Culture supernatants frommmunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc. 761
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Counterconversion and Retinoic AcidFigure 2. Retinoic Acid Influences the Expression of a Discrete Group of Genes that Are Largely Independent of the Canonical Treg Cell
Genomic Signature
(A) Comparison of probe-expression values in Foxp3+ T cells after culture with anti-CD3, TGF-b, and: lamina propria DCs (y axis) or spleen DCs (x axis), left panel;
or spleen DCs with (y axis) or without (x axis) RA (100 nM), right pannel. Probes highlighted in red and blue correspond to genes either upregulated or downregu-
lated (respectively) in the canonical Treg cell genomic signature.
(B) signatureMatch heat-map analysis of the Treg cell genomic signature in ex vivo Treg cells or TGF-b-converted cells (groups 3 and 4 are from Hill et al., 2007).
Raw expression values were normalized to 1 or zero for ex vivo Treg cells or Tconv cells, respectively. The expression values for genes from the TGF-b-converted
cells were normalized within this range (for a detailed description of the algorithm, see Supplemental Experimental Procedures) and displayed as a heat map, in
which red represents the expression of a gene at the same or a greater level than what is found in an ex vivo Treg cell, whereas black represents the expression of762 Immunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc.
Immunity
Counterconversion and Retinoic AcidFigure 3. Retinoic Acid Downregulates the IL-6Ra, but Enhancement of Foxp3 Expression by RA Occurs in the Absence of IL-6
(A) Expression of IL-6Ra is downregulated in CD4+ T cells by RA. Splenocytes (13 105) were activated with anti-CD3 and anti-CD28 beads in the absence (TGF,
open histogram) or presence of RA (TGF+RA, dark-gray histogram). Representative FACS plots are shown (n = 6 independent experiments).
(B) CD4+ T cells from Rara/ mice do not downregulate the IL-6 receptor after culture with RA. CD4+ T cells (0.53 105) from WT or Rara/ mice were activated
with anti-CD3 and anti-CD28 beads and TGF-b (10 ng/ml) in the absence (open histogram) or presence (filled histogram) of RA (100nM). Representative FACS
plots are shown (n = 3 independent experiments).
(C) RA prevents the inhibition of Foxp3 expression mediated by IL-6 in CD4+ T cells activated with TGF-b. CD4+ T cells (0.53 105) were activated with anti-CD3
and anti-CD28 beads and various concentrations of RA. After 24 hr, TGF-b (10 ng/ml) and IL-6 were added, and cells were cultured for an additional 4 days.
Representative FACS data are shown for Foxp3 expression in CD4+ T cells (n = 3 independent experiments).
(D) RA enhances Foxp3 expression in CD4+ T cells in the absence of IL-6. Splenocytes from WT or Il6/mice were stimulated (as in [A]) and analyzed 4 days later
for Foxp3 expression in CD4+ T cells. Representative FACS plots are shown (n = 3 independent experiments).CD44hi cells grown under the same conditions as the coculture
of Figure 5A (anti-CD3 and anti-CD28 beads, TGF-b) were in-
deed able to mediate the inhibition of Foxp3 induction (although
this dampening by supernatants was never quite as effective as
when cells were added directly—compare Figures 5C and 5D).
Preliminary time-course analyses showed that production of
the inhibitory factor(s) required stimulation of the CD44hi popula-
tion, peaking at 48 hr of culture (not shown). Thus, the impact of
CD44hi cells can be explained, at least in part, by the production
of soluble inhibitors.
This observation prompted us to ask how RA affects counter-
conversion activity. Conceptually, RA might prevent the produc-
tion of inhibitory factors by CD44hi cells, or it might decrease the
sensitivity of responder naive cells. These two alternatives were
tested in the experiments illustrated in Figures 5E and 5F. Treat-
ment of the responder naive cells with RA had no impact on their
susceptibility to inhibitory supernatant (Figure 5E). In contrast,
treatment of the CD44hi population did reduce the production
of inhibitory factor(s) in the supernatants (Figure 5F).
As an independent confirmation that RA signaled through the
CD44hi population, rather than through the naive converting cells
themselves, we exploited the identification of RARa, the primary
receptor in this context, and conducted mixed cell experiments
using naive or memory populations from Rara/ mice or con-
genically marked wild-type (WT) mice (Figure 5G). Under these
conditions, expression of Foxp3 in naive cells from Rara/
mice could still be increased by RA. In contrast, RA was withouteffect when memory cells from Rara/ mice were cocultured
with WT naive cells. As expected, the genotype of the naive
T cells was immaterial (Figure 5G). Thus, the primary mode of
action of RA in enhancing the conversion to a Foxp3+ phenotype
appears to be through the reduction of inhibitory factors
produced by CD44hi cells.
Counterconversion Results from Synergistic
Cytokine Action
We then sought to identify the soluble factor(s) mediating coun-
terconversion. Such a factor should have two characteristics:
be produced by CD44hi CD4+ cells and be reduced by RA treat-
ment. Triplicate microarray profiles were generated on CD45-
allotype-marked CD44hi cells in stimulated cocultures prepared
exactly as in Figure 5, and these were compared with or without
RA treatment. The results are displayed on the Expression versus
FoldChange plot of Figure 6A, in which Gene Ontology identifiers
were used for identifying cytokines and proteins released in the
extracellular space (shown as red dots). Several factors immedi-
ately stood out in this analysis, matching criteria of both transcript
abundance and repression by RA: IL-4, IL-9, IL-10, IL-21, and
Interferon-g (IFN-g). This analysis also confirmed the RA respon-
siveness of these cells, given that RA-responsive transcripts
identified in Figure 2 were also found differentially expressed in
CD44hi cells (i.e., Itga4 and Ccr9). In contrast, the vast majority
of secreted proteins were unaffected by RA or were even induced
(e.g., granulin). Counterconversion was not likely to be mediateda gene that is at the same or a lower level than that found in an ex vivo Tconv cell. Numbers to the right of the diagram show the average score for each group
across the entire signature.
(C) FcFc plot comparing the effects of RA in Foxp3+ TGF-b-converted cells (y axis) with ex vivo Treg cells (x axis).
(D) FcFc plot comparing the effects of RA in Foxp3+ (y axis) and Foxp3 (x axis) TGF-b-treated cells.Immunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc. 763
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transcript.
In order toconfirm the regulation of expression of some of these
cytokines by RA, we performed intracellular staining of the mem-
ory cells (identified in the cocultures as CD45.2+) after activation
for 48 hr. Clear reductions in IL-10 and IL-4 production were
evident in memory T cells treated with RA (Figure S3). Somewhat
surprisingly, we did not see the same trend for IFN-g, possibly
due to a more complex posttranscriptional regulation. Notably,
none of these cytokines were detected in naive CD44 T cells
cultured under the same conditions (not shown).
We then tested the effect of these candidate cytokines on
TGF-b-induced conversion of naive CD4+ cells (Figure 6B). IL-9
Figure 4. Retinoic Acid Acts Indirectly on Foxp3 Expression
(A) RA does not enhance TGF-b-mediated Foxp3 expression in purified naive
CD4+ T cells. Naive CD25CD44loCD62Lhi CD4+ T cells (0.5 3 105) were acti-
vated with anti-CD3 and anti-CD28 beads and TGF-b (10 ng/ml) in the absence
(left panel) or presence (middle panel) of RA (100 nM) for 4 days. Representa-
tive FACS data are shown for Foxp3 expression with the results of multiple
experiments plotted in the right panel (n = 6, p value for Student’s t test).
(B) RA does enhance TGF-b-mediated Foxp3 expression in CD4+ T cells from
unfractionated splenocytes. Splenocytes (0.53 105) were activated in vitro (as
in [A]) in the absence (left panel) or presence (middle panel) of RA (100 nM) for
4 days. Representative FACS data are shown for Foxp3 expression in CD4+
T cells with the results of multiple experiments plotted in the right panel
(n = 6, p value for Student’s t test).
(C) RA does not enhance Foxp3 expression in purified naive CD4+ T cells over
a range of TGF-b concentrations. Naive CD4+ T cells (purified as in [A]) were
activated with anti-CD3 and anti-CD28 beads in the presence of 100 nM RA
and the indicated doses of TGF-b, then analyzed at day 4 for Foxp3 expression
by FACS. Representative data are shown for three independent experiments.
(D) Foxp3 expression is not enhanced in naive CD4+ T cells over a range of RA
doses. Naive CD4+ T cells were activated (as in [A]) in the presence of the
indicated concentrations of RA, then analyzed for Foxp3 expression by
FACS. Summarized data from three independent experiments is shown.764 Immunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc.and IL-10 had no effect. IL-21 was inhibitory as expected, but
only at relatively high doses. IFN-g had a modest effect, but
IL-4 led to a marked decrease of Foxp3 expression, consistent
with recent studies (Wei et al., 2007; Mantel et al., 2007). Anti-
body-blockade experiments were performed for determining
which of these cytokines played the most important part in coun-
terconversion in coculture experiments (Figure 6C). Blocking
IL-21 or IFN-g individually had little or no effect, but anti-IL-4
antibodies had a significant impact on counterconversion activ-
ity (the importance of IL-4 was also apparent from the use of
CD44hi cells from Il4/ mice; Figure S4). Pairwise combinations
of antibodies had little more effect than did each alone, but
blockade of all three cytokines was more effective at eliminating
counterconversion activity, albeit still incompletely (Figure 6C). It
should also be noted that these blocking antibodies did not
affect Foxp3 expression in cultures with naive T cells only, paral-
leling the insensitivity to RA that was seen (data not shown).
This result prompted us to further explore whether these cyto-
kines act synergistically to inhibit Foxp3 expression by adding
them back to conversion cultures of purified naive T cells at
suboptimal doses (Figure 6D). At the doses used, IFN-g and
IL-21 had little effect on their own and IL-4 lead to only a partial
reduction in Foxp3 expression. Limited synergy was seen when
cytokines were added in pairs; for example, IL-21 enhanced the
inhibitory effects of IFN-g and IL-4. The largest reduction of
Foxp3 expression was seen when all three cytokines were added
at once, confirming their three-way synergy.
Thus, CD44hi memory T cells release of a set of cytokines that
inhibit TGF-b-driven Foxp3 expression. Their effect seems to be
elicited by their combined and synergistic action, rather than by
any of them alone, and RA inhibits the transcription of the whole
panel.
RA Acts Indirectly on Antigen-Specific
Conversion in GALT
To verify the in vivo relevance of the indirect mode of RA action
demonstrated in vitro, we exploited the known role of RARa in
the process, asking how the same WT CD4+ T cells would con-
vert when transferred into WT or Rara/ hosts. We used as a
model Foxp3-negative OT-II T cells transferred into hosts also
fed with oral ovalbumin. This model of in vivo antigen-specific
conversion is restricted to the GALT, because conversion does
not occur in subcutaneous lymph nodes or in spleen (Sun
et al., 2007). Consistent with previous findings, transferring OT-II
Rag1/ T cells (identifiable with a CD45.1 allotype and devoid of
any detectable Foxp3+ cells) to either WT or Rara/ hosts led to
detectable conversion in both the lamina propria and the mesen-
teric lymph nodes of ova-fed mice (Figure 7A; as expected, no
conversion was observed in the spleen or other lymph nodes);
OT-II cells in WT recipients showed a 2-fold higher proportion
of Foxp3-positive cells compared to those in Rara/ hosts
(Figure 7B). These data provide direct evidence that RA signaling
via RARa affects Foxp3 induction in vivo in an indirect manner,
through cells other than the naive CD4+ cells.
DISCUSSION
This study set out to elucidate the molecular mechanisms by
which RA promotes the TGF-b-induced conversion of naive
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did not observe major effects of RA on the responding cells. There
was no enhancement of TGF-b signaling and no complementa-
tion of the Treg cell transcriptional signature, and the conse-
quences of RA treatment on gene expression were relatively
modest and largely shared between Foxp3-positive and Foxp3-
negative cells in the same cultures. Instead, the data point to
a rather different mode of action, in which RA counteracts the
dampening effects of inhibitory populations whose existence
was revealed by cell fractionation and complementation analy-
ses. RA’s activity was entirely mediated by RARa, which provided
a useful experimental handle for confirmation of this indirect
effect through crisscross experiments, in vitro and in vivo.
The use of purified CD4+ cells in the assays allowed us to
discern the indirect effect of RA and the impact of countercon-
version mediated by CD44hi cells. In contrast, the ability of RA
to repress IL-6Ra in naive T cells, which would reduce their
susceptibility to inhibition by IL-6, also suggests the possible
existence of direct effects. Although this direct effect appeared
of secondary importance in our culture conditions, it may be
more prominent in some in vivo situations, where IL-6 made by
non-T cells may be more important. RA would thus safeguard
TGF-b-induced conversion in several settings.
An indirect effect of RA is compatible with the observation
made by most groups that the compound has no effect whatso-
ever in the absence of TGF-b, which is understandable if it serves
to relieve a repression rather than to directly promote conversion.
That RA would interact with inhibitory cells is also compatible with
the fact that there was substantial variability in the baseline effi-
cacy of conversion (as noted by Benson et al., 2007): most likely,
the actual proportion of CD44hi cells in the input population varied
between donor pools. The conditions used for these cultures
(engagement of CD3 and/or CD28, IL-2 supplementation, DCs)
were conducive to cytokine production, and one can conceive
of how small experimental variation might affect counterconver-
sion. In fact, the nature of the activating stimulus may modulate
the efficacy of RA in enhancing TGF-b-driven Foxp3 expression.
It is currently unclear whether counterconversion may also
affect other modes of T cell differentiation elicited by TGF-b. In
these cocultures, even with high concentrations of T cell-derived
IL-21, we found no evidence for IL-17 production at the protein or
mRNA level. Thus, there is clearly more than a dichotomous set
of possible outcomes (Foxp3 or IL-17 expression) for naive
T cells stimulated with TGF-b.
The ability of CD4+ Tconv cells to convert to a Foxp3+ pheno-
type when stimulated in a TGF-b-rich environment has been
proposed as a means for achieving a balanced and regulated
response, particularly in mucosal areas, such as the GALT,
where peaceful coexistence (if not actual tolerance) must be
achieved with the intestinal commensal flora. The ability to
generate Treg cells when intestinal homeostasis is threatened
is thus desirable, but it is also important that the system limit
the potential for a ‘‘runaway’’ conversion to Treg cell pheno-
types, which would overly suppress needed responses. The
existence of a counterconversion pathway would be a logical
means for controlling this potential; a balance between TGF-
b-fueled drive to conversion and counterconversion activity. In
this context, RA would serve as an external modulator of this bal-
ance. It is provided by a third-party cell, and one can conceive ofthe DCs acting as sensors and integrators of local microbial chal-
lenge and inflammatory responses, influencing the conversion/
counterconversion balance by releasing variable amounts of
RA. The particular ability of gut DCs to produce RA (Iwata
et al., 2004; Coombes et al., 2007) is clearly in line with such a
notion.
Intriguingly, RA has little to no influence on the selection of Treg
cells in the thymus, nor on their overall proportions in secondary
lymphoid organs, as evidenced by the normal Treg cell popula-
tions in Rara-deficient mice. This is compatible with a view in
which RA-influenced conversion of conventional CD4+ T cells
to a Foxp3+ phenotype represents a focused adaptation, involv-
ing only particular reactivities or locations, but overall homeo-
static control of Treg cell populations falls under a different
control, such as the supply of trophic cytokines.
The dampening of Foxp3 induction by cytokines showed clear
synergistic effects. IL-4 was the most active in this respect, but
IL-21 and IFN-g clearly enhanced this ability, and they comple-
mented each other in doing so. This synergy is unusual for IL-4
and IFN-g, which are usually antagonistic. It will be important
to elucidate the signaling pathways involved, but one can imag-
ine complex interactions wherein one cytokine induces the
receptor or the signaling cascade downstream of the other.
It should also be pointed out that, although counterconversion
can be mediated by cytokines in this synergistic fashion, soluble
factors do not account for the whole effect of CD44hi cells. Su-
pernatants from CD44hi cells were never quite as effective as
the cells themselves, and inhibition of counterconversion with
antibody combinations only incompletely reversed the inhibitory
effect. Although these elements could be explained by focused
release and action of cytokines or by additional soluble media-
tors, they also suggest that cell-cell interactions may be involved
in counterconversion.
What cells mediate counterconversion? The results indicate
that the function resides, at least in part, in CD44hi CD4+
T cells. It does not involve NKT cells, a priori attractive candi-
dates because of their ability to produce IL-4 and IFN-g: sorted
NK1.1-positive cells within the CD44hi fraction had no counter-
conversion ability (not shown). Similarly, Treg cells themselves
did not show activity (a priori an appealing hypothesis in which
Treg cells would negatively feed back on their own generation),
given that purified Foxp3-GFP+ cells added to the cultures did
not influence conversion (not shown). In contrast, countercon-
version ability was found in the CD44hi subset of CD8+ T cells,
suggesting that the activity resides in populations of antigen-
experienced Tconv cells with markers consistent with effector
and/or memory cells.
In fairness, although the concept of counterconversion is
logical and has operational value, we do not know whether a ded-
icated ‘‘counterconvertor’’ population exists. Such a label does
carry the teleological connotation of a distinct and identifiable
population whose role (or one of whose roles) is to maintain the
conversion or counterconversion balance. An alternative sce-
nario is one in which there is no such uniquely identifiable popu-
lation but rather a set of differentiated states that produce a set of
cytokines that dampen TGF-b-mediated Foxp3 induction. This
effect could be instilled in an antigen- or location-specific manner
and perpetuate the dominance of effective T cell responses, by
inhibiting the neogeneration of Treg cells, even in locations ofImmunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc. 765
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Counterconversion and Retinoic AcidFigure 5. CD44hi Memory CD4 T Cells Restrain TGF-b-Mediated Foxp3 Expression in Naive CD4 T Cells
(A) Naive CD25CD44loCD62Lhi CD4+ T cells (0.53 105) were activated with anti-CD3 and anti-CD28 beads and TGF-b (10 ng/ml) in the absence or presence of
RA (100 nM). These cells were cultured either alone or in combination with CD25CD44hiD62Llo memory CD4+ T cells (0.53 105 memory cells to 0.253 105 naive
cells) for 4 days. For comparison, CD44hi memory T cells were also cultured alone (under identical conditions as those for naive cells that were cultured alone).
Individual populations were tracked with the use of CD45.1 or CD45.2 congenic markers. Foxp3 expression in congenically marked populations was determined
by FACS, and a representative experiment is shown.
(B) FACS analysis for Foxp3 expression in multiple experiments as described in (A) (n = 14–19). Statistically significant differences were determined by Student’s
t test.766 Immunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc.
Immunity
Counterconversion and Retinoic Acidstrong TGF-b exposure. Whether one or several cell types affect




C57BL/6J (CD45.1 congenic), C57BL/6J, C57BL/6-H2g7, C57BL/6-Il6/,
and C57BL/6-Il4/ mice were bred in the SPF Joslin facility or purchased
from Jackson Laboratories. Rar-deficient mice (Chapellier et al., 2002a; Chap-
ellier et al., 2002b; Chapellier et al., 2002c) were bred in the SPF facility at
IGBMC, whereas Foxp3-eGFP reporter mice (Bettelli et al., 2006) and OT-II
Rag1/ (CD45.1 congenic) mice were bred in the SPF facility at NIAID.
Cells
Cells used for in vitro activation and in vivo transfer were obtained from spleen
and lymph nodes or lamina propria of 6- to 8-wk-old mice. Unless otherwise
noted, cells were sorted to obtain individual T cell or DC subpopulations.
Cell Sorting and Flow Cytometry
For Figures 1 and 2, CD4+CD25 T cells or CD4+Foxp3-eGFP T cells and
lamina propria DCs (LP DC) or spleen DCs (Sp DC) were isolated as described
previously (Sun et al., 2007). For experiments subsetting CD4+ cell types, naive
cells were sorted as B220,CD8,CD11c,CD25,CD4+,CD44CD62Lhi,
whereas the ‘‘memory’’ pool was sorted as B220,CD8,CD11c,CD25,
CD4+,CD44hiCD62Llo. OT-II Rag1/ CD45.1 CD4+ T cells were sorted as a
naive population (as described above but without staining for CD62L). Postac-
tivation analysis assessed CD4, CD45.1, CD45.2, a4b7, CCR9, IL6Ra, Foxp3,
IL-10, IL-4, or IFN-g expression by cell-surface and intracellular antibody
staining.
In Vitro Activation
For conversion assays, T cells were activated with anti-CD3 and anti-CD28
beads (Dynal) at a concentration of one bead per cell in the presence of
20 U/ml recombinant human IL-2 (Proleukin, Chiron) and 10 ng/ml recombinant
TGF-b (Peprotech), for 4 days in a 96-well plate. Naive CD4+ T cells were
cultured at a concentration of 0.5 3 105 per well, or 0.25 3 105 per well when
used in coculture assays. Memory CD4+ T cells were seeded at a 2:1
(memory:naive) cell ratio in coculture experiments (unless otherwise noted).
Some cultures were also treated with all-trans RA (100 nM unless otherwise
noted; Sigma), recombinant mouse IL-4, IL-6, IL-9, IL-10, IL-21, or IFN-g (at
the indicated concentrations; Peprotech), or blocking antibodies specific for
IL-6Ra, IL-4, IL-21, or IFN-g (5 mg/ml; R&D Systems). For the assays of Figures
1 and 2, 105 CD4+CD25 or CD4+eGFP T cells were cultured with 0.1 3 105
purified LP or Sp DCs in the presence of anti-CD3 (1 mg/ml), TGF-b (3 ng/ml),
IL-2 (5 ng/ml), and RA (10 or 100 nM) as described previously (Sun et al., 2007).In Vivo Conversion Assay
OT-II RAG-1/ CD45.1 CD4+ T cells (0.5–13 106 per mouse) were transferred
i.v. into either Rara/or WT littermate controls as described previously (Sun
et al., 2007). The drinking water of recipient mice was supplemented with 1.5%
ovalbumin and changed every 2 days. Mice were sacrificed 7 days after T cell
transfer, and Foxp3 expression in CD45.1+ donor T cells was detected in skin-
draining lymph nodes, spleen, mesenteric lymph node, and the lamina propria.
Microarrays
RNA was prepared from sorted cell populations as described previously
(Trizol; Yamagata et al., 2004). RNA was amplified for two rounds (Messa-
geAmp aRNA, Ambion), biotin-labeled (BioArray High Yield RNA Transcription
Labeling, Enzo), and purified with the RNeasy Mini Kit (QIAGEN). The resulting
cRNAs were hybridized to M430 2.0 chips (Affymetrix). All cell populations an-
alyzed were generated in duplicate or triplicate. Raw data were normalized
with the RMA algorithm implemented in the ‘‘Expression File Creator’’ module
from the GenePattern software package (Reich et al., 2006). Data were
visualized with the ‘‘Multiplot’’ module from GenePattern.
ACCESSION NUMBERS
The NCBI GEO accession number for the microarray data reported in this
paper is GSE13306.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and three
figures and can be found with this paper online at http://www.immunity.com/
S1074-7613(08)00472-X.
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CD44hi memory T cells to naive T cells (0.53 105). Cells were activated (as in [A]) and analyzed for Foxp3 expression 4 days later. Data presented are represen-
tative of three independent experiments.
(D) Supernatant from CD44hi CD4+ T cells activated with anti-CD3 and anti-CD28 beads for 48 hr can inhibit Foxp3 expression in naive T cells. Naive T cells were
activated with anti-CD3 and anti-CD28 beads and TGF-b (10 ng/ml) in the presence or absence of 100 ul of memory T cell supernatant and analyzed for Foxp3
expression 4 days later.
(E) Naive T cells were activated with anti-CD3 and anti-CD28 beads and the indicated concentrations of RA for 24 hr, then cultured in the presence of TGF-b
(10 ng/ml) and the indicated concentration of supernatant from memory T cells for 4 days. Representative FACS data from one of three experiments are shown.
Data are presented as percentage of Foxp3 expression in the test condition relative to that found in naive T cells alone (control).
(F) Memory T cells were activated and cultured in the presence or absence of RA. Supernatants were harvested at different time points and added to naive T cells
in the conversion assay. Representative FACS data from one of three experiments is shown. Data are presented as percentage of Foxp3 expression in the test
condition relative to that found in naive T cells alone (control).
(G) Crisscross experiments with Rara/ memory (left panel) or naive (right panel) CD4+ T cells in coculture with congenically marked WT naive (left panel) or
memory (right panel) CD4+ T cells were conducted as described in (A). No enhancement of Foxp3 expression was seen when Rara/ memory CD4+ T cells
were cultured with WT naive CD4+ T cells in the presence of RA. A significant enhancement (p < 0.01) of Foxp3 expression was seen when Rara/ naive
CD4+ T cells were cultured with WT memory CD4+ T cells in the presence of RA. Representative FACS plots are shown with the mean and SD from three
independent experiments.Immunity 29, 758–770, November 14, 2008 ª2008 Elsevier Inc. 767
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